Similar articles for PMID: 26508675

Year	Number of Results
2006	1
2007	1
2008	2
2009	3
2010	4
2011	2
2012	3
2013	2
2014	8
2015	16
2016	17
2017	16
2018	7
2019	10
2020	12
2021	5
2022	5
2024	0

1

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.

Aso Y, Fukushima M, Sagara M, Jojima T, Iijima T, Suzuki K, Momobayashi A, Kasai K, Inukai T. Aso Y, et al. Diabetes Res Clin Pract. 2015 Dec;110(3):250-6. doi: 10.1016/j.diabres.2015.10.012. Epub 2015 Oct 20. Diabetes Res Clin Pract. 2015. PMID: 26508675 Clinical Trial.

2

Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.

Pinheiro MM, Stoppa CL, Valduga CJ, Okuyama CE, Gorjão R, Pereira RM, Diniz SN. Pinheiro MM, et al. Eur J Pharm Sci. 2017 Mar 30;100:17-24. doi: 10.1016/j.ejps.2016.12.040. Epub 2017 Jan 5. Eur J Pharm Sci. 2017. PMID: 28065853

3

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.

Aso Y, Jojima T, Iijima T, Suzuki K, Terasawa T, Fukushima M, Momobayashi A, Hara K, Takebayashi K, Kasai K, Inukai T. Aso Y, et al. Endocrine. 2015 Dec;50(3):659-64. doi: 10.1007/s12020-015-0688-5. Epub 2015 Jul 25. Endocrine. 2015. PMID: 26209038 Clinical Trial.

4

Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.

Fukui K, Kawahito H, Wakana N, Kikai M, Terada K, Yamamoto K, Irie D, Kato T, Miyagawa S, Yamada H. Fukui K, et al. J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1001-9. doi: 10.1177/1470320315587180. Epub 2015 Jul 20. J Renin Angiotensin Aldosterone Syst. 2015. PMID: 26195265 Free article. Clinical Trial.

5

Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial.

Wang X, Yang L, Cheng Y, Zheng P, Hu J, Huang G, Zhou Z. Wang X, et al. J Diabetes Investig. 2019 Mar;10(2):375-382. doi: 10.1111/jdi.12873. Epub 2018 Aug 3. J Diabetes Investig. 2019. PMID: 29883070 Free PMC article. Clinical Trial.

6

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Hermansen K, et al. Diabetes Obes Metab. 2007 Sep;9(5):733-45. doi: 10.1111/j.1463-1326.2007.00744.x. Epub 2007 Jun 26. Diabetes Obes Metab. 2007. PMID: 17593236 Clinical Trial.

7

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus.

Sromova L, Busek P, Posova H, Potockova J, Skrha P, Andel M, Sedo A. Sromova L, et al. Diabetes Res Clin Pract. 2016 Aug;118:183-92. doi: 10.1016/j.diabres.2016.06.020. Epub 2016 Jun 18. Diabetes Res Clin Pract. 2016. PMID: 27388675

8

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.

Kato H, Nagai Y, Ohta A, Tenjin A, Nakamura Y, Tsukiyama H, Sasaki Y, Fukuda H, Ohshige T, Terashima Y, Sada Y, Kondo A, Sasaoka T, Tanaka Y. Kato H, et al. Diabetes Res Clin Pract. 2015 Jul;109(1):199-205. doi: 10.1016/j.diabres.2015.04.008. Epub 2015 Apr 20. Diabetes Res Clin Pract. 2015. PMID: 25934525 Clinical Trial.

9

Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.

Hattori A, Takemoto M, Tokuyama H, Koshizaka M, Yokote K. Hattori A, et al. Diabetes Res Clin Pract. 2017 Apr;126:138-143. doi: 10.1016/j.diabres.2017.02.010. Epub 2017 Feb 16. Diabetes Res Clin Pract. 2017. PMID: 28237860 Clinical Trial.

10

Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study.

Tanimura-Inagaki K, Nagao M, Harada T, Sugihara H, Moritani S, Sasaki J, Kono S, Oikawa S; SLIM Study Investigators. Tanimura-Inagaki K, et al. Diabetes Res Clin Pract. 2020 Apr;162:108119. doi: 10.1016/j.diabres.2020.108119. Epub 2020 Mar 17. Diabetes Res Clin Pract. 2020. PMID: 32194219 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year